Race Oncology is pleased to announce that it has entered into a collaborative preclinical research…
Race Oncology Ltd (ASX:RAC) has welcomed preclinical findings on the anti-cancer efficacy of bisantrene, which demonstrate its potential in enhancing the cancer-killing activity of the widely used drug doxorubicin across a diverse range of 143 human cancer cell lines. Read more here